Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
4.730
-0.340 (-6.71%)
Nov 21, 2024, 11:34 AM EST - Market open
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2023. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,490,308
Market Cap
88.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| 23andMe Holding Co. | 582 |
| FONAR | 520 |
| Karyopharm Therapeutics | 325 |
| Coherus BioSciences | 306 |
| PetMed Express | 287 |
| Adagene | 174 |
| Immunic | 77 |
| Assembly Biosciences | 65 |
NVCT News
- 6 days ago - Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Benzinga
- 16 days ago - Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 24 days ago - PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
- 3 months ago - Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers - GlobeNewsWire
- 3 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 7 months ago - Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 8 months ago - Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines - GlobeNewsWire